Table 2.
Association of serum HOXA11-AS with clinicopathological characteristics in patients with gastric cancer
| Clinical feature | Cases | Serum HOXA11-AS | P-value |
| Gender | 0.824 | ||
| Male | 57 | 0.345 ± 0.104 | |
| Female | 37 | 0.349 ± 0.091 | |
| Age (yr) | 0.304 | ||
| <60 | 38 | 0.337 ± 0.111 | |
| ≥60 | 56 | 0.355 ± 0.089 | |
| Tumor size (cm) | 0.001 | ||
| <5 | 59 | 0.320 ± 0.094 | |
| ≥5 | 35 | 0.391 ± 0.092 | |
| TNM stage | 0.001 | ||
| I and II | 39 | 0.250 ± 0.073 | |
| III and IV | 55 | 0.415 ± 0.040 | |
| Differentiation | 0.934 | ||
| Well and moderate | 50 | 0.346 ± 0.112 | |
| Poor | 44 | 0.347 ± 0.084 | |
| Invasion depth | 0.867 | ||
| T1 and T2 | 41 | 0.348 ± 0.100 | |
| T3 and T4 | 53 | 0.345 ± 0.099 | |
| Lymph node metastasis | 0.011 | ||
| Positive | 50 | 0.377 ± 0.088 | |
| Negative | 44 | 0.312 ± 0.100 |